Clinical Performance of Self-Collected Nasal Swabs and Antigen Rapid Tests for SARS-CoV-2 Detection in Resource-Poor Settings
Biomedicine
; 10(9): 1-9, Set 19, 2022. Tab, fig
Article
en En
| RSDM
| ID: biblio-1523208
Biblioteca responsable:
MZ1.1
ABSTRACT
Background:
In resource-poor countries, antigen-based rapid tests (Ag-RDTs) performed at primary healthcare and community settings improved access to SARS-CoV-2 diagnostics. However, the technical skills and biosafety requirements inherent to nasopharyngeal and oropharyngeal (OP) specimens limit the scale-up of SARS-CoV-2 testing. The collection of nasal-swabs is programmatically viable, but its performance has not been evaluated in resource-poor settings.Methods:
We first evaluated the performance of SteriPack self-collected nasal swabs for the detection of SARS-CoV-2 by real-time PCR in 1498 consecutively enrolled patients with suspected infection. Next, we evaluated the clinical performance of three nasal swab-based Ag-RDTs against real-time PCR on OP specimens.Results:
The sensitivity of nasal swabs was 80.6% [95% CI 75.3−85.2%] compared to OP specimens. There was a good correlation (r = 0.58; p < 0.0001) between Ct values of 213 positive cases obtained using nasal and OP swabs. Our findings show sensitivities of 79.7% [95% CI 73.3−85.1%] for Panbio COVID-19 Ag-RDT, 59.6% [95% CI 55.2−63.8%] for COVIOS Ag-RDT, and 78.0% [95% CI 73.5−82.0%] for the LumiraDx SARS-CoV-2 Ag-RDT.Conclusions:
In our setting, the COVIOS Ag-RDT did not meet WHO requirements. Nasal swab-based Ag-RDTs for SARS-CoV-2 detection constitute a viable and accurate diagnostic option in resource-poor settingsPalabras clave
Texto completo:
1
Colección:
06-national
/
MZ
Banco de datos:
RSDM
Asunto principal:
Prueba de COVID-19
/
Prueba Serológica para COVID-19
Límite:
Humans
País/Región como asunto:
Africa
Idioma:
En
Revista:
Biomedicine
Año:
2022
Tipo del documento:
Article